Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Hepatitis C: early-phase trial registry
13 of 108 indexed Hepatitis C trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #119 of 28,707 conditions by registered trial count.
108 US clinical trials · 13 currently recruiting · #119 of 28,707 conditions by registered trial count
Hepatitis C: 108 US clinical trials tracked, 13 recruiting.
Hepatitis C is the subject of 108 registered US clinical trials on ClinicalTrials.gov, 13 of them currently open to new participants. 21 are in Phase 3-4 (later-stage) and 37 in Phase 1-2 (earlier-stage). The most active sponsor is Gilead Sciences, running 7 of these trials.
Enrollment posture brief
Registry condition hepatitis-c
OPEN 13 | RECR 12% | LATE 21 | EARLY 37 | RANK #119 | SPON 7
Volume-matched condition peers
Nearest open-share peer: HIV Infection (12% recruiting · 74 trials)
Hepatitis C lists 13 open slots (12% of 108 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Hepatitis C on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Hepatitis C is recruiting below its size-band peers.
13 of 108 indexed trials (12%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Hepatitis C trials is spread across many organizations.
Gilead Sciences accounts for 7 of 108 trials (6.5%). 67 distinct sponsors appear on at least one study for this condition label.
-
Typical Hepatitis C enrolment sits around 115 participants.
Median target enrolment is 115 among the 107 trials that report a genuine target (sentinel values excluded). 49 of those (45.8%) plan for fewer than 100 participants.
-
Hepatitis C research is mostly interventional.
86 interventional and 22 observational studies make up this index (79.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
108 total, page 1 of 3
Evaluation of Patients With Liver Disease
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT00001971
The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing
University of Chicago
NCT01280825
Proteogenomic Monitoring and Assessment of Liver Transplant Recipients
Northwestern University
NCT01644903
Blood Collection Biorepository for Liver Disease Research
State University of New York at Buffalo
NCT03025074
The HOPE Study: Characterizing Patients With Hepatitis B and C
University of Maryland, Baltimore
NCT02995252
Partner Navigation Intervention for Hepatitis C Treatment Among Young People Who Inject Drugs
University of California, San Francisco
NCT06179498
The Hepatitis C Transplant Collaborative
Baylor Research Institute
NCT04493385
Project I Test: Implementing HIV Testing in Opioid Treatment Programs
Columbia University
NCT03135886
Use of a Patient-Centered Electronic App to Increase ED Patient's Knowledge on HCV to Improve the HCV Care Continuum
Johns Hopkins University
NCT04162938
DBS TaT in Peer-assisted Telemedicine for Hepatitis C
Oregon Health and Science University
NCT06409169
The Treatment in Pregnancy for Hepatitis C ("TiP-HepC") Registry
The Task Force for Global Health
NCT05368974
Feasibility and Acceptability of HCV Treatment in Pregnancy
Washington University School of Medicine
NCT06367465
HCV Tappt Adherence Study
University of Illinois at Chicago
NCT06263829
A Study to Evaluate Preemptive Therapy in Hepatitis C (HCV) Organ Transplant Recipients
Mayo Clinic
NCT04508907
Tele-Harm Reduction
University of Miami
NCT05208697
Advanced Care Coordination and Enhanced Linkage and Retention Among Transitional Re-Entrants
Montefiore Medical Center
NCT04701437
The Use of Hepatitis C Positive Kidneys in Hepatitis C Negative Kidney Transplant Recipients
Amit D Tevar, MD
NCT03809533
Buprenorphine Integration Research and Community Health
Yale University
NCT05668780
Expanding the Pool in Orthotopic Heart Transplantation
Mary E. Keebler, MD
NCT03222531
The DETECT HCV Screening Trial
Denver Health and Hospital Authority
NCT04003454
HCV-TARGET- Hepatitis C Therapeutic Registry and Research Network
University of North Carolina, Chapel Hill
NCT01474811
Improving Inpatient Screening for Hepatitis C
University of Pennsylvania
NCT04525690
Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir and Sofosbuvir/Velpatasvir in Adults With Chronic HCV Infection Who Have Not Previously Received Treatment With Direct-Acting Antiviral Therapy
Gilead Sciences
NCT02607800
Genetics of Hepatitis C Virus Infection
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT00005657
An Observational Study of Hepatitis C Virus in Pregnancy
The George Washington University Biostatistics Center
NCT01959321
Patient-Centered Models of HCV Care for People Who Inject Drugs
Prisma Health-Upstate
NCT02824640
Long Term Follow-up Study to Assess Durability of Sustained Virologic Response in Alisporivir-treated Hepatitis C Patients
Debiopharm International
NCT02753699
Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 2)
Boehringer Ingelheim
NCT01297270
Does Induction PEG-Intron in Combination With Rebetol Enhance the Sustained Response Rates in Patients With CHC
Brooke Army Medical Center
NCT00207363
Study Comparing Daclatasvir (BMS-790052) With Telaprevir Combined With Peginterferon Alfa-2a and Ribavirin in Patients With Chronic Hepatitis C Virus Infection
Bristol-Myers Squibb
NCT01492426
SOF (Sovaldi®) +RBV for 16 or 24 Weeks and SOF+RBV+Peg-IFN for 12 Weeks in Adults With Genotype 2 or 3 Chronic HCV Infection
Gilead Sciences
NCT01962441
Long-Term Study of Liver Disease in People With Hepatitis B and/or Hepatitis C With or Without HIV Infection
National Institutes of Health Clinical Center (CC)
NCT01350648
Phase 3 Study of Sofosbuvir and Ribavirin
Gilead Sciences
NCT01497366
Integrating HIV and Hepatitis C Screening in an Urban Emergency Department
New York City Health and Hospitals Corporation
NCT03252483
Efficacy and Safety of Adding Alisporivir (DEB025) to Peginterferon (IFN) Alfa-2a (Peg-IFN Alfa-2a) and Ribavirin in Chronic HCV Genotype 1 Patients Who Relapsed or Did Not Respond to Previous Treatment
Debiopharm International
NCT01183169
Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir in Adults With Chronic HCV Infection Who Have Previously Received Treatment With Direct-Acting Antiviral Therapy
Gilead Sciences
NCT02607735
Virology Follow up Study in Subjects Previously Treated With Telaprevir
Vertex Pharmaceuticals Incorporated
NCT00916474
Hepatitis C Antiviral Resistance in African-Americans
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT00038974
Monitoring SOF/VEL in Treatment Naïve, HCV Participants With Active Infection
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
NCT03512210
An Efficacy, Safety and Tolerability Study of TMC435 in Genotype 1 Hepatitis C-infected Patients Who Relapsed After Previous Therapy
Janssen R&D Ireland
NCT01281839
The Kentucky Viral Hepatitis Treatment Study
Jennifer Havens
NCT03949764
Collection of Plasma and Serum Samples From Individuals Initiating Sofosbuvir for Chronic Hepatitis C for Testing
Hologic
NCT02068963
Brain Deficits in HIV/HCV Coinfected People Before and After Anti-HCV Therapy
University of California, Los Angeles
NCT00747539
Integrated Stepped Care for Unhealthy Alcohol Use in HIV
Yale University
NCT01410123
Merimepodib (MMPD) in Triple Combination for the Treatment of Chronic Hepatitis C
Vertex Pharmaceuticals Incorporated
NCT00088504
Study of Liver Transplant For End-Stage Liver Disease Caused By Chronic Hepatitis C Infection
Baylor Research Institute
NCT00163657
Hepatitis C Translating Initiatives for Depression Into Effective Solutions
VA Office of Research and Development
NCT01143896
Comparing Brief Alcohol Interventions For HIV-HCV Co-infected Persons
Butler Hospital
NCT02316184
A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV
Atea Pharmaceuticals
NCT05904470
A Study Evaluating the Safety and Clinical Activity of HCV-796 in Treatment-Naive and Non-Responder Subjects
Wyeth is now a wholly owned subsidiary of Pfizer
NCT00367887
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 14 |
| Phase 2 | 23 |
| Phase 3 | 11 |
| Phase 4 | 10 |
Top Sponsors
Named interventions
Most-linked intervention names on Hepatitis C records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Hepatitis C trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Hepatitis C page
108 registered trials, 13 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 13 Hepatitis C trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Gilead Sciences sponsors the most Hepatitis C trials on record, review their full trial history before evaluating a specific study. See Gilead Sciences's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Hepatitis C condition card totals 108 registered trials; most-linked intervention Ribavirin; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.